June 2019 - Volume 3 - Issue S1 - Contributor Index

Author:
Ta, F.

PS1518 GENOME EDITING OF HBG1/2 PROMOTER LEADS TO ROBUST HBF INDUCTION IN VIVO, WHILE EDITING OF BCL11A ERYTHROID ENHANCER RESULTS IN ERYTHROID DEFECTS

Heath, J.; de Dreuzy, E.; Sanchez, M.; More

HemaSphere. 3(S1):699-700, June 2019.

Author:
Ta, T.

PS1518 GENOME EDITING OF HBG1/2 PROMOTER LEADS TO ROBUST HBF INDUCTION IN VIVO, WHILE EDITING OF BCL11A ERYTHROID ENHANCER RESULTS IN ERYTHROID DEFECTS

Heath, J.; de Dreuzy, E.; Sanchez, M.; More

HemaSphere. 3(S1):699-700, June 2019.

Author:
Tabayashi, T.
Author:
Tabbaa, D.

PS1518 GENOME EDITING OF HBG1/2 PROMOTER LEADS TO ROBUST HBF INDUCTION IN VIVO, WHILE EDITING OF BCL11A ERYTHROID ENHANCER RESULTS IN ERYTHROID DEFECTS

Heath, J.; de Dreuzy, E.; Sanchez, M.; More

HemaSphere. 3(S1):699-700, June 2019.

PF670 MOLECULAR CLASSIFICATION OF PATIENTS WITH POLYCYTHEMIA VERA OR ESSENTIAL THROMBOCYTHEMIA WHO DEVELOP RESISTANCE OR INTOLERANCE TO HYDROXYUREA

Díaz, Á.; Larrán, A. Álvarez; Casterá, E. Mora; More

HemaSphere. 3(S1):288, June 2019.

Author:
Taborda, G.
Author:
Tacchetti, P.

PF560 A MATURATION INDEX DEFINES NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS WITH ADVANCED IMMUNOPHENOTYPIC AND MOLECULAR DIFFERENTIATION PROFILES ASSOCIATED WITH POOR PROGNOSIS

Martello, M.; Termini, R.; Borsi, E.; More

HemaSphere. 3(S1):232, June 2019.

Author:
Tachawong, N.
Author:
Tachdjian, G.

PS1498 INCREASED RHOA ACTIVITY DUE TO A DISRUPTED FILAMIN A/ALPHAIIBBETA3 INTERACTION INDUCES MACROTHROMBOCYTOPENIA

Donada, A.; Balayn, N.; Sliwa, D.; More

HemaSphere. 3(S1):690, June 2019.

Author:
Tachi, N.

PS1435 SLAMF7 HIGH CD16 NEGATIVE MONOCYTES INCREASE IN PERIPHERAL BLOOD OF PATIENTS WITH MYELOFIBROSIS IN CORRELATION WITH JAK2V617F MUTATION

Kato, S.; Maekawa, T.; Ogata, K.; More

HemaSphere. 3(S1):661-662, June 2019.

Author:
Tachita, T.

PS1367 COMPREHENSIVE GENETIC ANALYSIS OF MULTIPLE MYELOMA IN JAPAN

Kanamori, T.; Sanada, M.; Ri, M.; More

HemaSphere. 3(S1):624-625, June 2019.

PF191 RECLASSIFICATION OF BIPHENOTYPIC ACUTE LEUKEMIA INTO MIXED-PHENOTYPE ACUTE LEUKEMIA ACCORDING TO WHO CRITERIA REFINES PATIENT CHARACTERIZATION AND PROGNOSIS; DISEASE MARKERS AND IMPACT ON OUTCOME

Douka, V.; Kotta, K.; Chatziioannidis, A.; More

HemaSphere. 3(S1):47-48, June 2019.

Author:
Tada, K.

PF623 PHASE 1/2 STUDY OF ISATUXIMAB MONOTHERAPY FOR RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA IN JAPANESE PATIENTS

Iida, S.; Sunami, K.; Ri, M.; More

HemaSphere. 3(S1):265, June 2019.

Author:
Tadele, D.

S835 MASS CYTOMETRY REVEAL EARLY SIGNALING RESPONSES TO INDUCTION THERAPY IN IMMUNOPHENOTYPICALLY DEFINED LEUKEMIC CELL SUBSETS THAT PREDICT SURVIVAL IN AML

Tislevoll, B.S.; Fagerholt, O.H.E.; Hellesøy, M.; More

HemaSphere. 3(S1):371-372, June 2019.

Author:
Tadmor, B.
Author:
Tadmor, T.
Author:
Tafulo, S.
Author:
Tafuri, A.

PS1343 ARE MYELODYSPLASTIC SYNDROMES WITH ISOLATED 20Q DELETION A DIFFERENT CLINICAL-BIOLOGICAL ENTITY?

Campagna, A.; De Benedittis, D.; Fianchi, L.; More

HemaSphere. 3(S1):613, June 2019.

Author:
Tafuri, M.

PB2386 BEHAVIOUR OF CIRCULATING ENDOTHELIAL CELLS IN AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS WITH MULTIPLE MYELOMA

Annibali, O.; Gregorj, C.; Tomarchio, V.; More

HemaSphere. 3(S1):1061-1062, June 2019.

Author:
Taghon, T.

S860 TARGETING ABERRANT DNA METHYLATION AS A NOVEL AND UNIFORM THERAPEUTIC STRATEGY FOR THE TREATMENT OF T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA AND LYMPHOMA

Thenoz, M.; Roels, J.; Reunes, L.; More

HemaSphere. 3(S1):384-385, June 2019.

Author:
Tagliaferri, E.

PF758 MULTI-CENTER, PHASE II STUDY ON HAPLOIDENTICAL BONE MARROW TRANSPLANTATION USING A RIC REGIMEN AND POST-TRANSPLANT CYCLOPHOSPHAMIDE IN PATIENTS WITH POOR PROGNOSIS LYMPHOMAS

Castagna, L.; Dodero, A.; Patriarca, F.; More

HemaSphere. 3(S1):333, June 2019.

Author:
Tagliaferri, L.
Author:
Tagliaferri, P.

S121 SINGLE-CELL CHARACTERIZATION OF THE MULTIPLE MYELOMA (MM) IMMUNE MICROENVIRONMENT IDENTIFIES CD27- T CELLS AS POTENTIAL SOURCE OF TUMOR-REACTIVE LYMPHOCYTES

Botta, C.; Perez, C.; Puig, N.; More

HemaSphere. 3(S1):12-13, June 2019.

Author:
Tagliafico, E.

PF655 PROGNOSTIC RELEVANCE OF THE GENE EXPRESSION SIGNATURE IN PRIMARY AND SECONDARY MYELOFIBROSIS

Rontauroli, S.; Zini, R.; Bianchi, E.; More

HemaSphere. 3(S1):280-281, June 2019.

Author:
Tagliavini, A.
Author:
Taguchi, M.

S135 NGS-BASED COPY-NUMBER ANALYSIS IN MORE THAN 2,000 PATIENTS WITH MYELOID NEOPLASMS

Saiki, R.; Shiozawa, Y.; Yoshizato, T.; More

HemaSphere. 3(S1):19-20, June 2019.

Author:
Taha, G.
Author:
taha, H.
Author:
Taha, R. Y

PF583 COMPREHENSIVE ANALYSIS OF THE COMPLEXITY AND HETEROGENEITY OF THE LNCRNAS TRANSCRIPTOME IN MULTIPLE MYELOMA

Carrasco-Leon, A.; Ezponda, T.; Meydan, C.; More

HemaSphere. 3(S1):243, June 2019.

Author:
Taha, R.Y.

PF567 CHROMATIN ACTIVATION AS A UNIFYING PRINCIPLE UNDERLYING PATHOGENIC MECHANISMS IN MULTIPLE MYELOMA

Ordoñez, R.; Kulis, M.; Russiñol, N.; More

HemaSphere. 3(S1):236, June 2019.

Author:
Taher, A.
Author:
Tai, Y.-T.

PF600 IGH TRANSLOCATIONS WITH UNDEFINED PARTNERS ARE ASSOCIATED WITH SUPERIOR OUTCOME IN MULTIPLE MYELOMA PATIENTS

Mao, X.-H.; An, G.; Xu, Y.; More

HemaSphere. 3(S1):253-254, June 2019.

Author:
Taiana, E.

PS1360 LONG NON-CODING RNA NEAT1 TARGETING TRIGGERS ANTI-TUMOR ACTIVITY AND RESULTS IN CHEMO-SENSITIZING EFFECT IN MULTIPLE MYELOMA CELLS

Taiana, E.; Favasuli, V.K.; Ronchetti, D.; More

HemaSphere. 3(S1):621, June 2019.

Author:
Taja-Chayeb, L.
Author:
Tajana, M.

PF227 PROGNOSTIC VALUE OF CLONAL HEMATOPOIESIS-MUTATIONS DETECTED AT DIAGNOSIS IN ACUTE MYELOID LEUKEMIA PATIENTS WITH NORMAL KARYOTYPE

Caprioli, C.; Spinelli, O.; Salmoiraghi, S.; More

HemaSphere. 3(S1):65-66, June 2019.

Author:
Tajima, A.

PS1110 THE IDENTIFICATION OF A COMMON LOSS-OF-FUNCTION MUTATION ACROSS DIFFERENT HLA CLASS ALLELES FREQUENTLY DETECTED IN PATIENTS WITH ACQUIRED APLASTIC ANEMIA

Mizumaki, H.; Hosomichi, K.; Tanabe, M.; More

HemaSphere. 3(S1):503, June 2019.

Author:
Takahashi, H.

PS1115 THE RELATIONSHIP BETWEEN THE PRETREATMENT PNH CLONE SIZE AND CLINICAL COURSE IN PATIENTS WITH BONE MARROW FAILURE SYNDROMES: INTERIM ANALYSIS OF JAPANESE MULTICENTER PROSPECTIVE STUDY

Ueda, Y.; Hosokawa, K.; Ishiyama, K.; More

HemaSphere. 3(S1):504-505, June 2019.

PB2055 HIGH PREVALENCE OF NON-GERMINAL CENTER B-CELL PHENOTYPE WITH MYC OVEREXPRESSION IN JAPANESE PATIENTS WITH INTRAVASCULAR LARGE B-CELL LYMPHOMA

Takahashi, H.; Nakanishi, Y.; Miura, K.; More

HemaSphere. 3(S1):927, June 2019.

Author:
Takahashi, K.

PF212 NEXT-GENERATION SEQUENCING OF CIRCULATING CELL-FREE DNA PROVIDES COMPLEMENTARY INFORMATION TO GENOMIC PROFILING OF BONE MARROW IN PATIENTS WITH ACUTE LEUKEMIAS

Short, N.; Patel, K.; Albitar, M.; More

HemaSphere. 3(S1):58, June 2019.

PF291 A PHASE 1B/2 CLINICAL STUDY OF TARGETED IDH1 INHIBITION WITH IVOSIDENIB, IN COMBINATION WITH THE BCL-2 INHIBITOR VENETOCLAX, FOR PATIENTS WITH IDH1-MUTATED (MIDH1) MYELOID MALIGNANCIES

Dinardo, C.; Takahashi, K.; Kadia, T.; More

HemaSphere. 3(S1):97, June 2019.

PF673 PHASE 1/2 STUDY OF RUXOLITINIB (RUX) PLUS DECITABINE (DAC) IN PATIENTS (PTS) WITH POST-MYELOPROLIFERATIVE NEOPLASM ACUTE MYELOID LEUKEMIA (POST-MPN AML)

Bose, P.; Verstovsek, S.; Naqvi, K.; More

HemaSphere. 3(S1):289-290, June 2019.

S833 THE SINGLE-CELL ATLAS OF DRIVER MUTATIONS IN AML

Morita, K.; Wang, F.; Jahn, K.; More

HemaSphere. 3(S1):370, June 2019.

PS1064 EXPLORATORY ANALYSIS OF OUTCOMES WITH SEQUENTIAL FLT3-INHIBITOR (FLT3I) BASED THERAPIES IN RELAPSED FLT3-MUTATED AML PATIENTS (PTS)

Alfayez, M.; Kantarjian, H.; Ravandi, F.; More

HemaSphere. 3(S1):481-482, June 2019.

PS1180 FOLLOW-UP OF LOWER DOSE DASATINIB 50MG DAILY AS FRONTLINE THERAPY IN NEWLY DIAGNOSED CHRONIC PHASE CHRONIC MYELOID LEUKEMIA (CML-CP)

Naqvi, K.; Jabbour, E.; Skinner, J.; More

HemaSphere. 3(S1):537, June 2019.

S1615 SAFETY, EFFICACY, AND BIOMARKERS OF RESPONSE TO AZACITIDINE (AZA) WITH NIVOLUMAB (NIVO) AND IPILIMUMAB (IPI), AND AZA WITH NIVO IN R/R ACUTE MYELOID LEUKEMIA: A NON-RANDOMIZED, PHASE 2 STUDY.

Daver, N.; Alfayez, M.; Garcia-Manero, G.; More

HemaSphere. 3(S1):745, June 2019.

Author:
Takahashi, N.

PF411 ENESTOP 192-WK RESULTS: DURABILITY AND IMPACT ON QUALITY OF LIFE OF TREATMENT-FREE REMISSION (TFR) FOLLOWING SECOND-LINE (2L) NILOTINIB (NIL) IN PATIENTS (PTS) WITH CHRONIC MYELOID LEUKEMIA (CML)

Mahon, F.-X.; Boquimpani, C.; Takahashi, N.; More

HemaSphere. 3(S1):158, June 2019.

Author:
Takahashi, S.

PB2339 GASTROINTESTINAL BLEEDING WAS ASSOCIATED WITH WORSE SURVIVAL IN PATIENTS WITH GASTROINTESTINAL ACUTE GRAFT-VERSUS-HOST DISEASE: SINGLE CENTER RETROSPECTIVE STUDY

Harada, S.; Minauchi, K.; Senjo, H.; More

HemaSphere. 3(S1):1042-1043, June 2019.

Author:
Takahashi, Y.
Author:
Takamatsu, H.

PF623 PHASE 1/2 STUDY OF ISATUXIMAB MONOTHERAPY FOR RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA IN JAPANESE PATIENTS

Iida, S.; Sunami, K.; Ri, M.; More

HemaSphere. 3(S1):265, June 2019.

PS1110 THE IDENTIFICATION OF A COMMON LOSS-OF-FUNCTION MUTATION ACROSS DIFFERENT HLA CLASS ALLELES FREQUENTLY DETECTED IN PATIENTS WITH ACQUIRED APLASTIC ANEMIA

Mizumaki, H.; Hosomichi, K.; Tanabe, M.; More

HemaSphere. 3(S1):503, June 2019.

Author:
Takami, A.

PF756 DONOR UNC-93 HOMOLOG B1 GENETIC VARIATION PREDICTS SURVIVAL OUTCOMES AFTER UNRELATED BONE MARROW TRANSPLANTATION

Uchino, K.; Mizuno, S.; Horio, T.; More

HemaSphere. 3(S1):332, June 2019.

Author:
Takami, H.
Author:
Takami, K.
Author:
Takamori, H.

PS1115 THE RELATIONSHIP BETWEEN THE PRETREATMENT PNH CLONE SIZE AND CLINICAL COURSE IN PATIENTS WITH BONE MARROW FAILURE SYNDROMES: INTERIM ANALYSIS OF JAPANESE MULTICENTER PROSPECTIVE STUDY

Ueda, Y.; Hosokawa, K.; Ishiyama, K.; More

HemaSphere. 3(S1):504-505, June 2019.

Author:
Takano, K.

PS1435 SLAMF7 HIGH CD16 NEGATIVE MONOCYTES INCREASE IN PERIPHERAL BLOOD OF PATIENTS WITH MYELOFIBROSIS IN CORRELATION WITH JAK2V617F MUTATION

Kato, S.; Maekawa, T.; Ogata, K.; More

HemaSphere. 3(S1):661-662, June 2019.

Author:
Takao, T.
Author:
Takaori, A.

PF407 TREATMENT-FREE REMISSION IN PATIENTS WITH CHRONIC MYELOGENOUS LEUKEMIA FOLLOWING FIRST-LINE DASATINIB, 1ST DADI/IMIDAS4

Murai, K.; Kimura, S.; Imagawa, J.; More

HemaSphere. 3(S1):155-156, June 2019.

S135 NGS-BASED COPY-NUMBER ANALYSIS IN MORE THAN 2,000 PATIENTS WITH MYELOID NEOPLASMS

Saiki, R.; Shiozawa, Y.; Yoshizato, T.; More

HemaSphere. 3(S1):19-20, June 2019.

PS983 NOVEL MOLECULAR PATHOGENESIS AND THERAPEUTIC TARGET IN ACUTE ERYTHROID LEUKEMIA

Takeda, J.; Shih, L.-Y.; Yoshida, K.; More

HemaSphere. 3(S1):442, June 2019.

Author:
Takashima, S.
Author:
Takasugi, S.

PF756 DONOR UNC-93 HOMOLOG B1 GENETIC VARIATION PREDICTS SURVIVAL OUTCOMES AFTER UNRELATED BONE MARROW TRANSPLANTATION

Uchino, K.; Mizuno, S.; Horio, T.; More

HemaSphere. 3(S1):332, June 2019.

Author:
Takayama, N.

PF784 COMPARISON OF ALEMTUZUMAB, ANTI-THYMOCYTE GLOBULIN AND POST-TRANSPLANT CYCLOPHOSPHAMIDE FOR ACUTE GRAFT-VS-HOST DISEASE AND GRAFT-VS-LEUKEMIA EFFECT IN XENOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION

Mashima, K.; Oh, I.; Fujiwara, K.; More

HemaSphere. 3(S1):345-346, June 2019.

PS1259 LONG-TERM FOLLOW-UP OF JCOG0406 STUDY: INTENSIVE IMMUNOCHEMOTHERAPY (R-HIGH CHOP/CHASER) FOLLOWED BY HIGH-DOSE CHEMOTHERAPY (LEED) WITH AUTO-PBSCT IN UNTREATED MANTLE CELL LYMPHOMA

Ogura, M.; Yamamoto, K.; Morishima, Y.; More

HemaSphere. 3(S1):575-576, June 2019.

Author:
Takeda, J.

S135 NGS-BASED COPY-NUMBER ANALYSIS IN MORE THAN 2,000 PATIENTS WITH MYELOID NEOPLASMS

Saiki, R.; Shiozawa, Y.; Yoshizato, T.; More

HemaSphere. 3(S1):19-20, June 2019.

PF532 INTEGRATED PROFILING OF DNA METHYLATION AND MUTATIONS IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES

Morimoto, S.; Makishima, H.; Nagata, Y.; More

HemaSphere. 3(S1):218-219, June 2019.

PS983 NOVEL MOLECULAR PATHOGENESIS AND THERAPEUTIC TARGET IN ACUTE ERYTHROID LEUKEMIA

Takeda, J.; Shih, L.-Y.; Yoshida, K.; More

HemaSphere. 3(S1):442, June 2019.

Author:
Takei, M.

PB2055 HIGH PREVALENCE OF NON-GERMINAL CENTER B-CELL PHENOTYPE WITH MYC OVEREXPRESSION IN JAPANESE PATIENTS WITH INTRAVASCULAR LARGE B-CELL LYMPHOMA

Takahashi, H.; Nakanishi, Y.; Miura, K.; More

HemaSphere. 3(S1):927, June 2019.

Author:
Takeshita, J.

PS1277 EVALUATION OF THE IMMUNITY TO MEASLES, MUMPS AND RUBELLA IN ADULT PATIENTS AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION

Kawamura, K.; Nakasone, H.; Wada, H.; More

HemaSphere. 3(S1):584-585, June 2019.

S1639 SAFETY AND EFFICACY OF LIVE ATTENUATED VARICELLA VACCINE FOR PREVENTING VARICELLA ZOSTER VIRUS DISEASE AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: A PROSPECTIVE SINGLE-CENTER STUDY

Kawamura, K.; Nakasone, H.; Akahoshi, Y.; More

HemaSphere. 3(S1):758, June 2019.

Author:
Takeuchi, M.
Author:
Takeuchi, Y.

PF532 INTEGRATED PROFILING OF DNA METHYLATION AND MUTATIONS IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES

Morimoto, S.; Makishima, H.; Nagata, Y.; More

HemaSphere. 3(S1):218-219, June 2019.

Author:
Takezako, N.

PF407 TREATMENT-FREE REMISSION IN PATIENTS WITH CHRONIC MYELOGENOUS LEUKEMIA FOLLOWING FIRST-LINE DASATINIB, 1ST DADI/IMIDAS4

Murai, K.; Kimura, S.; Imagawa, J.; More

HemaSphere. 3(S1):155-156, June 2019.

PF591 EFFICACY AND SAFETY OF DARATUMUMAB, LENALIDOMIDE, AND DEXAMETHASONE (D-RD) IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): UPDATED SUBGROUP ANALYSIS OF POLLUX BASED ON CYTOGENETIC RISK

Dimopoulos, M.A.; San-Miguel, J.; White, D.; More

HemaSphere. 3(S1):247-248, June 2019.

PS1370 ELOTUZUMAB PLUS POMALIDOMIDE AND DEXAMETHASONE FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA: EFFICACY RESULTS AFTER ADDITIONAL FOLLOW-UP OF THE PHASE 2, RANDOMIZED ELOQUENT-3 STUDY

Dimopoulos, M.; Dytfeld, D.; Grosicki, S.; More

HemaSphere. 3(S1):626-627, June 2019.

Author:
Takimoto, C.

S867 THE FIRST-IN-CLASS ANTI-CD47 ANTIBODY HU5F9-G4 WITH RITUXIMAB INDUCES DURABLE RESPONSES IN RELAPSED/REFRACTORY DLBCL AND INDOLENT LYMPHOMA: INTERIM PHASE 1B/2 RESULTS

Advani, R.; Bartlett, N.; Smith, S.; More

HemaSphere. 3(S1):388, June 2019.